Explores FOLFIRINOX's effectiveness in managing advanced pancreatic cancer, suggesting improved treatment approaches.
Whilst FOLFIRINOX achieves high initial disease control in advanced PDAC, its benefit is limited by substantial toxicity and poor durability. Only a minority of patients maintain disease control beyond 6 months, which is strongly associated with improved survival. These findings suggest a need to redefine 'valuable FOLFIRINOX chemotherapy' to encompass not only initial response but also sustained disease control, toxicity management, and shared decision-making to optimise the benefit of FOLFIRINOX for patients.
No takes yet. Share an insight, caveat, or question.
Strijk et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: